SNHG17: A Potential Drug Target and Biomarker for Small Nucleolar RNA Host Genes

Target Name: SNHG17

NCBI ID: G388796

SNHG17

Other Name(s): small nucleolar RNA host gene 17 | SNHG17 variant 1 | Small nucleolar RNA host gene 17, transcript variant 1

SNHG17: A Potential Drug Target and Biomarker for Small Nucleolar RNA Host Genes

Small nucleolar RNA (snRNA) host genes are a class of non-coding RNAs that play a crucial role in the regulation of gene expression in eukaryotic cells. These genes are transcribed from DNA and can be processed into functional snRNAs that interact with various protein factors to help regulate gene expression. One of the known snRNA host genes is SNHG17, which is a potential drug target and biomarker for various diseases.

SNHG17: Structure and Function

SNHG17 is a 24.8 kilobase (kb) long RNA molecule that is encoded from the U1 snRNA gene. It is a part of the 5S rRNA gene family and is responsible for the production of the 5S rRNA subunit of the nuclear ribosome. SNHG17 is expressed in various cell types of the human body, including the brain, heart, and testes.

The function of SNHG17 is still under investigation, but it is known to play a role in the regulation of gene expression. Studies have shown that SNHG17 can interact with various protein factors, including the protein factors known as microRNA (miRNA) and long non-coding RNAs (lncRNA). These protein factors can help regulate the expression of target genes by binding to their respective cognate RNA molecules.

Drug Target Potential

SNHG17 has been identified as a potential drug target due to its involvement in the regulation of gene expression. The use of small molecules, such as drugs, to disrupt the interaction between SNHG17 and protein factors that regulate gene expression is a promising strategy for the development of new therapeutic approaches for various diseases.

One of the known drugs that can interact with SNHG17 is the small molecule IDHU-2241. This drug is currently being investigated for its potential therapeutic applications in various diseases, including cancer. IDHU-2241 is a inhibitor of the protein kinase B, which is known to interact with SNHG17. By inhibiting the activity of B, IDHU-2241 can help reduce the expression of genes that are regulated by SNHG17.

Biomarker Potential

SNHG17 has also been identified as a potential biomarker for various diseases. The expression of SNHG17 is known to be regulated by various factors, including gene expression, post-transcriptional modifications, and interactions with protein factors. Therefore, the expression level of SNHG17 can be used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and genetic disorders.

Conclusion

SNHG17 is a known snRNA host gene that plays a crucial role in the regulation of gene expression in eukaryotic cells. Its function is still under investigation, but it is known to interact with various protein factors that regulate gene expression. The potential drug target and biomarker status of SNHG17 make it an attractive target for the development of new therapeutic approaches for various diseases. Further research is needed to fully understand the role of SNHG17 in gene regulation and its potential as a drug target and biomarker.

Protein Name: Small Nucleolar RNA Host Gene 17

The "SNHG17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNHG17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets